Aditxt, Inc.

What they do

Aditxt, through its subsidiary Adimune, is developing Apoptotic DNA Immunotherapy (ADI), a platform designed to induce immune tolerance. Its lead candidate, ADI-100, targets glutamic acid decarboxylase (GAD) for type-1 diabetes, psoriasis, and central nervous system autoimmune diseases. The company has completed preclinical studies and is preparing for clinical trials in Germany and the U.S. (with Mayo Clinic). It has engaged a CRO for German trials and is working on an IND package for FDA submission.

Revenue drivers

• No commercial products — The company has generated minimal revenue, primarily from grants or other minor sources; no product sales to date.
• Grant or other income — Annual revenue was $3,195 in 2025 and $133,985 in 2024, indicating immaterial external funding.
• Potential future licensing or partnerships — Management is evaluating health innovations, but no licensing or partnership revenue has been reported.
• Research collaborations — Collaborations, such as with Mayo Clinic, may provide future funding but have not generated revenue as of the latest report.

Recent performance

For the year ended December 31, 2025, revenue was $3,195 with a net loss of $43.1 million, and operating cash flow was -$25.7 million. In Q1 2026 (ending March 31, 2026), revenue was $12,159, a slight increase from prior quarters, but cash and equivalents stood at only $268,852 as of that date. Total assets were $13.9 million against total liabilities of $49.1 million, leaving shareholder equity at -$33.3 million. The company has not generated significant commercial revenue and continues to rely on funding to support operations.

Strategy

Aditxt's strategy is to advance ADI-100 through regulatory approval and clinical development, focusing on Germany for psoriasis and T1D trials and the U.S. for Stiff Person Syndrome via a Mayo Clinic collaboration. The company intends to submit a complete dossier to regulatory agencies and is preparing for a pre-IND meeting with the FDA in Q2 2026. Management is also evaluating additional health innovations to expand the portfolio. The company raised capital through multiple equity sales and material agreements in mid-2026, indicating a reliance on external funding.

Risks

• Going concern risk — The company's financial situation raises substantial doubt about its ability to continue as a going concern, as stated in the 10-K risk factors.
• Cash runway is critically short — Cash and equivalents of $268,852 as of March 31, 2026, are insufficient to fund operations without additional capital.
• Regulatory and clinical delays — The company may face delays in clinical trials, which would require additional costs and could prevent timely regulatory approval.
• Nasdaq listing non-compliance — The company has received delisting notices and may not remain compliant with Nasdaq listing requirements, risking its stock exchange listing.

Outlook

Management expects a pre-IND meeting with the FDA in the second quarter of 2026 to review the ADI-100 package for SPS, with a human trial potentially starting in 2026. The company also plans to advance clinical trials in Germany for psoriasis and T1D, pending regulatory approvals. However, the outlook is heavily dependent on securing additional capital, as current cash levels are extremely low and ongoing losses are expected.